Search results

  1. LarsSG

    Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey, 2023, Massey

    Also, I just noticed that only 18 out of more than 1000 health administrators that they reached out to actually filled in their survey, which is concerning for risk of bias as well.
  2. LarsSG

    Typing myalgic encephalomyelitis by infection at onset: A DecodeME study, 2023, Bretherick et al

    They also report: "Participants reporting an infectious onset (when compared to those who did not) were also significantly more likely to report: improving symptoms, relapsing/remitting, or recovered (relative to ‘Fluctuating’) symptoms, and less likely to report worsening symptoms (again...
  3. LarsSG

    Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey, 2023, Massey

    Data was from surveying health administrators, so it is possible that this is an underestimate due to underreporting.
  4. LarsSG

    Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey, 2023, Massey

    Prevalence of LC severe enough that the students had to stop training was between 0-1.3%.
  5. LarsSG

    Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey, 2023, Massey

    Abstract Background Symptomatic COVID-19 and Long COVID, also referred to as post-acute sequelae of SARS-CoV-2 (PASC) or post-COVID conditions, have been widely reported in young, healthy people, but their prevalence has not yet been determined in student athletes. We sought to estimate the...
  6. LarsSG

    Trial Report A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled tria Lau 2023

    Yes, Zeynep and I had some back and forth on Twitter and she pointed out that they did say they asked the patients if they were mild, moderate or severe for each symptom. That they didn't report any results from that data suggests there weren't any, i.e. no significant change in severity. So...
  7. LarsSG

    Developing and validating a brief screening scale for ME/CFS, 2023, Jason et al

    It's frequency and severity over the last 6 months for these symptoms: 1. Fatigue/extreme tiredness 2. Minimum exercise makes you physically tired 3. Feeling unrefreshed after you wake up in the morning 4. Problems remembering things I've attached a PDF.
  8. LarsSG

    Dysregulation of tetrahydrobiopterin metabolism in ME/CFS by pentose phosphate pathway, 2024, Bulbule, Roy et al

    This is the preprint. See post #4 for the published paper Augmentation of Anaerobic Pentose Phosphate Pathway Dysregulates Tetrahydrobiopterin Metabolism in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) Patients with Orthostatic Intolerance: A Pilot Study Sarojini Bulbule, Carl...
  9. LarsSG

    Deriving and validating a risk prediction model for long COVID, 2023, Jeffrey et al

    Looks potential interesting, but it also looks like they included a lot of variables and with p = 0.022 this could just be noise. It also looks like being a carehome resident and having dementia are also protective; perhaps there is a correlation with those factors and parenteral anticoagulants...
  10. LarsSG

    Trial Report A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled tria Lau 2023

    I think Zeynep's got the wrong end of the stick there. It's true that the treatment didn't seem to eliminate any symptoms, but it seems fairly convincing that it improved fatigue with 63% versus 43% reporting improvement (answering yes to 4 of 5 questions about improvement). Similar results for...
  11. LarsSG

    Experiences of Canadians with long-term symptoms following COVID-19, 2023, Kuang et al

    This is an interesting, though not surprising, bit of data: "Among Canadians who reported ever experiencing longterm symptoms, females (33.0%) were less likely than males (53.1%) to report a resolution of their symptoms and experienced their symptoms longer on average" To be fair, there is...
  12. LarsSG

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    It seems like this question would be an obvious candidate for a health records based study. We've seen all kinds of EHR studies on LC, why not ME? I suspect the coding is poor and there would be some work needed to clean things up, but getting a lower bound for diagnosed ME doesn't seem like it...
  13. LarsSG

    Demystifying Long COVID International Conference Dec 2023

    Here's the video for day two. I found the talk from Brent Appelman, starting here, interesting. The first half is from a forthcoming study where they looked at muscle biopsies from LC patients and controls before and after a CPET. They found focal necrosis in muscle in about 40% of LC patients...
  14. LarsSG

    News from Canada

    "The current burden, measured in June 2023, is also substantial: 6.8% of all Canadian adults or 2.1 million people continue to experience long-term symptoms. On average, this group had their most recent COVID-19 infection 11 months prior."
  15. LarsSG

    Blood transcriptomics reveal persistent SARS-CoV-2 RNA and candidate biomarkers in Long COVID patients, 2024, Menezes et al.

    Published as a preprint. See post #7 And now published in final form - link here ****** This is an abstract from the Demystifying Long COVID International Conference 2023, converted from an image on Twitter, so it might be slightly wonky, but it looks intriguing. Blood Transcriptomics Reveal...
  16. LarsSG

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    Good point. Not sure we have evidence to say this effect would be strong enough to explain the difference, but it could be part of the explanation. I still have a hard time believing a full 2% of 50-59 year old Americans have a diagnosis of ME/CFS though (actual prevalence, maybe, but for...
  17. LarsSG

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    I wouldn't agree that recovery is rare. I think that's heavily influenced by sampling bias (easy for us to think of lots of people who have had ME for a long time, not so much people who were sick for a year or three and then got better, perhaps not ever really knowing what they had). I think...
  18. LarsSG

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    I think you have two factor that balance each other out to some degree. Many people who have ME are undiagnosed, but also if you ask people “Have you ever been told by a doctor or other health professional that you had Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME)?” some...
  19. LarsSG

    2023 Burnet Oration: Dr Ziyad Al-Aly

    I think what Al-Aly's papers are measuring is largely not ME-type LC. If you really look at their analysis, I think there are some pretty big selection bias problems, leading to overestimation of the outcomes they report. But even then, the outcomes they do report are mostly diagnoses of new...
Back
Top Bottom